Clinical trial

Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer

NCT07106528

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2025-08-01

PhasePHASE2 / PHASE3

Study timeline

Study start (estimated)2025-08-01Date precision: month

Registry last updated2025-08-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Extensive-stage Small Cell Lung Cancer (ES-SCLC)unresolved

Extensive-stage Small Cell Lung Cancer (SCLC)unresolved

Small Cell Lung Cancer ( SCLC )unresolved

Interventions

Organoid Drug Sensitivity Testing-Guided TherapyDRUG

TopotecanDRUG · verified · RxNorm: topotecan

Sponsors & collaborators

Peking Union Medical College Hospitallead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07106528 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.